Ketamine Response Rates: How to Understand the Percentages
Learn the difference between response and remission, the context behind one intravenous ketamine trial, and why a study percentage cannot predict outcomes from at-home compounded spray.
Share
There is no single response percentage that applies to everyone considering ketamine. A number is only useful when you know who was studied, what medication they received, how improvement was defined, and when researchers measured it.
Important: Compounded ketamine is not FDA-approved. FDA has not reviewed these products for safety, effectiveness, or quality before marketing. Ketamine is not FDA-approved for psychiatric conditions. Compounded nasal spray is different from FDA-approved esketamine (Spravato), which is administered in certified healthcare settings. Read FDA's explanation of compounded drugs.
What does “response” mean?
Depression trials often define response as a substantial reduction on a symptom-rating scale. Remission uses a different threshold for a low level of symptoms. Neither term automatically means a permanent recovery, and neither is the same as feeling different immediately after a dose.
An example with its limits
In a 2023 randomized trial involving adults with treatment-resistant major depression without psychosis, 55.4% in the intravenous ketamine group met the study's response definition during the initial three-week phase. Response meant at least a 50% reduction on a particular self-reported depression scale.
That percentage describes that study's participants and monitored intravenous treatment. It is not a Bliss Mist Rx outcome statistic or an estimate for compounded at-home nasal spray. The comparison, eligibility criteria, treatment schedule, and follow-up all affect how the result should be interpreted.
Questions to ask about any advertised success rate
- Was the study about this exact formulation and route?
- Were all enrolled patients counted, including people who stopped treatment?
- Was there a comparison group?
- Did “success” mean response, remission, satisfaction, or something else?
- How long did improvement last, and what adverse effects occurred?
What should you expect personally?
No percentage can promise your result. Ask your clinician how progress will be assessed and what would lead to changing or stopping the plan. Discuss alternatives as well as the cost and burden of follow-up.
Keeping a brief record of symptoms and daily functioning can make those conversations more concrete. Worsening symptoms or troublesome side effects deserve attention even if an advertisement reports a high average response rate.
Risks and the treatment setting
Ketamine can cause sedation, dissociation, impaired thinking or coordination, increased blood pressure, and slowed breathing. Abuse, misuse, dependence, worsening psychiatric symptoms, and urinary or bladder problems are additional concerns. A prescription or lower dose does not eliminate these risks.
At home, a healthcare professional is not onsite to monitor you or respond immediately to a serious reaction. Virtual visits and follow-up support do not provide the same monitoring as an onsite healthcare team. Discuss your medications, health history, monitoring needs, and emergency plan with your clinician.
Discuss your options
Bliss Mist Rx LLC provides telehealth services and does not compound or manufacture medications. A licensed clinician determines whether treatment is appropriate. A consultation does not guarantee a prescription. If prescribed, medication is dispensed by an independent, appropriately licensed compounding pharmacy.
Book a Free Virtual Appointment or Follow-Up.
This article is general education and does not replace individualized medical advice.
